Methods for treating renal cell carcinoma

a renal cell carcinoma and il2 technology, applied in the field of renal cell carcinoma treatment with il2, can solve the problems of severe side effects, neurological changes, fever and chills, etc., and achieve the effects of inhibiting tumor growth, reducing toxicity, and reducing side effects

Inactive Publication Date: 2007-01-18
NOVARTIS VACCINES & DIAGNOSTICS INC
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006] The present invention provides an efficacious method for treating renal cell carcinoma with IL-2. The method utilizes a relatively low dose of IL-2 compared to dosages used previously in high dose IL-2 therapies in order to reduce toxicity. As shown in the examples herein, this therapeutic regimen significantly inhibits tumor growth with reduced adverse side effects and provides an alternative treatment for patients who cannot tolerate high dose IL-2 therapy.

Problems solved by technology

However, high doses of IL-2 used to achieve positive therapeutic results with respect to tumor growth frequently cause severe side effects, including fever and chills, hypotension and capillary leak (vascular leak syndrome or VLS), and neurological changes (see, for example, Duggan et al., J.
However, the administration of high dose IL-2 is associated with capillary leak syndrome, which results in hypotension and reduced organ perfusion, which can be severe and sometimes fatal.
These toxicities have generally restricted the use of IL-2 to a highly selected group of patients administered by physicians with significant experience in its administration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating renal cell carcinoma
  • Methods for treating renal cell carcinoma
  • Methods for treating renal cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

example 1

Pharmaceutical Composition of IL-2 for Phase IV Human Clinical Trial

[0102] The IL-2 formulation used was manufactured by Chiron Corporation of Emeryville, Calif., under the tradename Proleukin®. The IL-2 in this formulation is a recombinantly produced, unglycosylated human IL-2 mutein, called aldesleukin, which differs from the native human IL-2 amino acid sequence in having the initial alanine residue eliminated and the cysteine residue at position 125 replaced by a serine residue (referred to as des-alanyl-1, serine-125 human interleukin-2). This IL-2 mutein is expressed in E. coli, and subsequently purified by diafiltration and cation exchange chromatography as described in U.S. Pat. No. 4,931,543, incorporated herein by reference in its entirety. The IL-2 formulation marketed as Proleukin® is supplied as a sterile, white to off-white preservative-free lyophilized powder in vials containing 1.3 mg of protein (22 MIU).

example 2

Selection Criteria for Patients with Metastatic Renal Cell Carcinoma for Treatment with IL-2 in Phase IV Human Clinical Trial

[0103] The following selection criteria were applied to patients with metastatic renal cell carcinoma:

[0104] Inclusion criteria: [0105] Patient has histologically documented renal cell carcinoma (clear cell, papillary, mixed or sarcomatoid tumors) with evidence of metastatic disease; [0106] Patient has measurable or evaluable neoplastic disease which is determined within four weeks of entering the study; [0107] Karnofsky Performance Status of patient is 60, corresponding to an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2; [0108] Patients must be greater than 18 years of age; [0109] Patients should have adequate renal function as evidenced by a serum creatinine level of less than 1.8 mg / dl; [0110] Hemoglobin 10 gm / dl; White blood cell 4,000 / ml; Platelet 100,000 / ml; [0111] Normal thyroid stimulating hormone (TSH) level; and [0112] P...

example 3

Phase IV Clinical Study of Low Dose IL-2 Administered to Humans

[0123] Clinical Study Design and Objectives

[0124] The Phase IV clinical study of interleukin-2 in an alternative dose (ILIAD) was designed as a prospective, multi-center, single-arm, open-label study to evaluate the efficacy and safety of low dose Proleukin® administered subcutaneously in patients with metastatic renal cell carcinoma. The primary endpoint was an objective response rate (ORR)≧16%. Secondary endpoints included complete response (CR) and partial response (PR) rates, duration of response, progression free survival (PF), overall survival (OS), and incidence of adverse events (AEs). Participants included clinical investigators from both community and academic settings, with a preponderance of community clinicians. The ILIAD study screened 270 patients, of which 267 were enrolled.

[0125] Pretreatment evaluations included a complete history, physical exam, complete blood count (CBC), serum chemistry panel, thy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and / or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims benefit under 35 U.S.C. § 119(e) of provisional application 60 / 647,496, filed Jan. 27, 2005, which application is hereby incorporated by reference in its entirety.TECHNICAL FIELD [0002] The present invention pertains generally to methods for treating renal cell carcinoma with IL-2. In particular, the invention relates to methods of treating renal cell carcinoma in patients who are renally impaired or intolerant of high-dose IL-2 therapy. BACKGROUND [0003] Interleukin-2 (IL-2) is a potent stimulator of natural killer (NK) and T-cell proliferation and function (Morgan et al. (1976) Science 193:1007-1011). This naturally occurring lymphokine has been shown to have anti-tumor activity against a variety of malignancies either alone or when combined with lymphokine-activated killer (LAK) cells or tumor-infiltrating lymphocytes (TIL) (see, for example, Rosenberg et al., N. Engl. J. Med. (1987) 316:889-897; Rosenberg, Ann...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/20
CPCA61K47/48215A61K38/2013A61K47/60A61P13/12A61P35/00A61P35/04A61K38/20
Inventor ELIAS, LAURENCEWITHERELL, GARY W.
Owner NOVARTIS VACCINES & DIAGNOSTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap